Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1997 Jan;71(1):720–725. doi: 10.1128/jvi.71.1.720-725.1997

Toward highly efficient cell-type-specific gene transfer with retroviral vectors displaying single-chain antibodies.

T H Chu 1, R Dornburg 1
PMCID: PMC191105  PMID: 8985404

Abstract

Recently, we constructed retroviral vector particles derived from spleen necrosis virus (SNV) that display a single-chain antibody (scA) on the viral surface. By transient transfection protocols, we showed that such particles are competent for infection and cell type specific. Efficient infection was dependent on the presence of wild-type envelope, although wild-type SNV was not infectious on target cells (T.-H. T. Chu and R. Dornburg, J. Virol. 69:2659-2663, 1995; T.-H. T. Chu, I. Martinez, W. C. Sheay, and R. Dornburg, Gene Ther. 1:292-299, 1994). In this study, stable packaging lines were constructed and detailed biological and biochemical studies were performed. Chimeric scA-envelope fusion proteins were expressed as efficiently as wild-type envelope and were stable over a period of at least 6 h. Only a fully functional wild-type envelope could act as a helper for efficient virus penetration. The ratio of wild-type envelope protein to chimeric envelope protein appears to determine the efficiency of infection. Virus titers of targeting vectors obtained from stable packaging lines were as high as 10(4) CFU/ml. A 25-fold concentration of vector virus stocks resulted in a 200-fold increase in virus titers (up to 10(6) CFU/ml). These data indicate that an inhibitor of infection was (at least partially) removed by the concentration protocol. Our data show that this technology has several variables for further improvements and, therefore, has the potential to become a powerful tool for cell-type-specific in vivo human gene therapy.

Full Text

The Full Text of this article is available as a PDF (431.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burns J. C., Friedmann T., Driever W., Burrascano M., Yee J. K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8033–8037. doi: 10.1073/pnas.90.17.8033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chu T. H., Dornburg R. Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer. J Virol. 1995 Apr;69(4):2659–2663. doi: 10.1128/jvi.69.4.2659-2663.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chu T. H., Martinez I., Olson P., Dornburg R. Highly efficient eukaryotic gene expression vectors for peptide secretion. Biotechniques. 1995 May;18(5):890-6, 898-9. [PubMed] [Google Scholar]
  4. Chu T. H., Martinez I., Sheay W. C., Dornburg R. Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins. Gene Ther. 1994 Sep;1(5):292–299. [PubMed] [Google Scholar]
  5. Cournoyer D., Caskey C. T. Gene therapy of the immune system. Annu Rev Immunol. 1993;11:297–329. doi: 10.1146/annurev.iy.11.040193.001501. [DOI] [PubMed] [Google Scholar]
  6. Cui Z. Z., Lee L. F., Silva R. F., Witter R. L. Monoclonal antibodies against avian reticuloendotheliosis virus: identification of strain-specific and strain-common epitopes. J Immunol. 1986 Jun 1;136(11):4237–4242. [PubMed] [Google Scholar]
  7. Dornburg R. Reticuloendotheliosis viruses and derived vectors. Gene Ther. 1995 Jul;2(5):301–310. [PubMed] [Google Scholar]
  8. Dropulić B., Jeang K. T. Gene therapy for human immunodeficiency virus infection: genetic antiviral strategies and targets for intervention. Hum Gene Ther. 1994 Aug;5(8):927–939. doi: 10.1089/hum.1994.5.8-927. [DOI] [PubMed] [Google Scholar]
  9. Etienne-Julan M., Roux P., Carillo S., Jeanteur P., Piechaczyk M. The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker. J Gen Virol. 1992 Dec;73(Pt 12):3251–3255. doi: 10.1099/0022-1317-73-12-3251. [DOI] [PubMed] [Google Scholar]
  10. Gilmore T. D., Temin H. M. Different localization of the product of the v-rel oncogene in chicken fibroblasts and spleen cells correlates with transformation by REV-T. Cell. 1986 Mar 14;44(5):791–800. doi: 10.1016/0092-8674(86)90845-7. [DOI] [PubMed] [Google Scholar]
  11. Hunter E., Swanstrom R. Retrovirus envelope glycoproteins. Curr Top Microbiol Immunol. 1990;157:187–253. doi: 10.1007/978-3-642-75218-6_7. [DOI] [PubMed] [Google Scholar]
  12. Kasahara N., Dozy A. M., Kan Y. W. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science. 1994 Nov 25;266(5189):1373–1376. doi: 10.1126/science.7973726. [DOI] [PubMed] [Google Scholar]
  13. Kawai S., Nishizawa M. New procedure for DNA transfection with polycation and dimethyl sulfoxide. Mol Cell Biol. 1984 Jun;4(6):1172–1174. doi: 10.1128/mcb.4.6.1172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Malhotra S., Scott A. G., Zavorotinskaya T., Albritton L. M. Analysis of the murine ecotropic leukemia virus receptor reveals a common biochemical determinant on diverse cell surface receptors that is essential to retrovirus entry. J Virol. 1996 Jan;70(1):321–326. doi: 10.1128/jvi.70.1.321-326.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Martinez I., Dornburg R. Improved retroviral packaging lines derived from spleen necrosis virus. Virology. 1995 Apr 1;208(1):234–241. doi: 10.1006/viro.1995.1147. [DOI] [PubMed] [Google Scholar]
  16. Martinez I., Dornburg R. Mapping of receptor binding domains in the envelope protein of spleen necrosis virus. J Virol. 1995 Jul;69(7):4339–4346. doi: 10.1128/jvi.69.7.4339-4346.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Martinez I., Dornburg R. Mutational analysis of the envelope protein of spleen necrosis virus. J Virol. 1996 Sep;70(9):6036–6043. doi: 10.1128/jvi.70.9.6036-6043.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Martinez I., Dornburg R. Partial reconstitution of a replication-competent retrovirus in helper cells with partial overlaps between vector and helper cell genomes. Hum Gene Ther. 1996 Apr 10;7(6):705–712. doi: 10.1089/hum.1996.7.6-705. [DOI] [PubMed] [Google Scholar]
  19. Mikawa T., Fischman D. A., Dougherty J. P., Brown A. M. In vivo analysis of a new lacZ retrovirus vector suitable for cell lineage marking in avian and other species. Exp Cell Res. 1991 Aug;195(2):516–523. doi: 10.1016/0014-4827(91)90404-i. [DOI] [PubMed] [Google Scholar]
  20. Morgan R. A., Anderson W. F. Human gene therapy. Annu Rev Biochem. 1993;62:191–217. doi: 10.1146/annurev.bi.62.070193.001203. [DOI] [PubMed] [Google Scholar]
  21. Roux P., Jeanteur P., Piechaczyk M. A versatile and potentially general approach to the targeting of specific cell types by retroviruses: application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9079–9083. doi: 10.1073/pnas.86.23.9079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Russell S. J., Hawkins R. E., Winter G. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res. 1993 Mar 11;21(5):1081–1085. doi: 10.1093/nar/21.5.1081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Sheay W., Nelson S., Martinez I., Chu T. H., Bhatia S., Dornburg R. Downstream insertion of the adenovirus tripartite leader sequence enhances expression in universal eukaryotic vectors. Biotechniques. 1993 Nov;15(5):856–862. [PubMed] [Google Scholar]
  24. Somia N. V., Zoppé M., Verma I. M. Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7570–7574. doi: 10.1073/pnas.92.16.7570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Young J. A., Bates P., Willert K., Varmus H. E. Efficient incorporation of human CD4 protein into avian leukosis virus particles. Science. 1990 Dec 7;250(4986):1421–1423. doi: 10.1126/science.2175047. [DOI] [PubMed] [Google Scholar]
  26. Yu M., Poeschla E., Wong-Staal F. Progress towards gene therapy for HIV infection. Gene Ther. 1994 Jan;1(1):13–26. [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES